Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Proinflammatory cytokines downregulated by Vasogen's immune modulation therapy

Dec. 19, 2000

EMEA hands down positive opinion for Rapamune

Dec. 12, 2000

Immunosuppressive drug in development at Isotechnika shows promise in phase I

Dec. 11, 2000

Epimmune licenses Valentis technology for vaccine development

Dec. 7, 2000

Phase I study results reported in San Francisco for MEDI-507 in GVHD

Dec. 6, 2000

Phase I safety and pharmacokinetic analysis of AP-1903 reported at Hematology meeting

Dec. 4, 2000

ABX-CBL granted orphan drug status for treatment of acute GVHD

Dec. 4, 2000

Clinical evaluation begins for QS-21-containing flu vaccine

Nov. 28, 2000

Heparan sulfate useful for inducing dendritic cell maturation for mounting a primary immune response

Nov. 27, 2000

Immunosuppressive profile of FTY-720 further defined in preclinical studies

Nov. 27, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...